Search clinical trials for: WU-CART-007

Total 17157 results

Oblato, Inc.

Available

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant

United States
Applied Therapeutics, Inc.

Active, not recruiting

AT-007 in Adult Subjects With Classic Galactosemia (CG)

Classic Galactosemia

United States
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects

Cerebral Apoplexy

China
AbbVie

Terminated

A Study of SC-007 in Subjects With Advanced Cancer

Gastric Cancer | Colorectal Cancer (CRC)

United States
Tigris Pharmaceuticals

Completed

A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) (TG-003)

Cervical Intraepithelial Neoplasia | Uterine Cervical Dysplasia

United States
DEKK-TEC, Inc.

Completed

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

HIV Infections | Lymphoproliferative Disorders | Sarcoma, Kaposi

United States
Morphotek

Terminated

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Metastatic Colorectal Cancer | Colorectal Cancer

United States
Recognify Life Sciences

Recruiting

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

Schizophrenia | Cognitive Impairment | Cognitive Impairment Associated With Schizophrenia (CIAS)

United States
Applied Therapeutics, Inc.

Completed

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

Classic Galactosemia

United States
Intra-Cellular Therapies, Inc.

Terminated

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Agitation in Dementia, Including Alzheimer's Disease

United States
Intra-Cellular Therapies, Inc.

Completed

Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

Alzheimer's Disease

United States
Inmagene LLC

Active, not recruiting

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

Healthy Volunteers

Australia
Shanghai East Hospital
Bio4T2 LLC

Recruiting

Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors

Advanced Solid Tumor

China
Erasca, Inc.

Active, not recruiting

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1)

Advanced or Metastatic Solid Tumors

United States
New York State Psychiatric Institute
Intra-Cellular Therapies, Inc.

Terminated

ITI-007 (Lumateperone Tosylate) for Schizophrenia

Schizophrenia

United States
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients in CHINA (QL-007)

Chronic Hepatitis b

China
Shanghai University of Traditional Chinese Medicine

Unknown

Study on the Treatment of Bronchial Asthma With Traditional Chinese Medicine

Bronchial Asthma

China
Shanghai East Hospital
Bio4T2 LLC

Active, not recruiting

A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China
EyeGene Inc.
Novotech (Australia) Pty Limited

Active, not recruiting

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

COVID-19 Vaccine

Australia
Intra-Cellular Therapies, Inc.

Completed

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

Bipolar Depression

United States, Russian Federation, Ukraine, Bulgaria, Serbia, Colombia
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

Bipolar Depression

United States
iCo Therapeutics Inc.

Completed

Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema

Diffuse Diabetic Macular Edema

United States
University of Aarhus
Odense University Hospital; Oslo University Hospital; Rigshospitalet, Denmark; Hvidovre... and other collaborators

Completed

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN)

HIV-1-infection

Norway, Denmark, United States, Australia
M.D. Anderson Cancer Center

Active, not recruiting

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Breast Inflammatory Carcinoma | Recurrent Breast Inflammatory Carcinoma | Stage IV Breast Inflammatory Carcinoma

United States
Hekabio

Completed

Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan

Breast Cancer | Head and Neck Cancer

Japan
Corvus Pharmaceuticals, Inc.

Completed

Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

COVID-19

United States
GeneScience Pharmaceuticals Co., Ltd.

Completed

GS3-007a Oral Solution in Healthy Subjects

Healthy Subject

China
Berlin Cures GmbH

Completed

The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor

Heart Failure | Cardiomyopathy, Dilated | Autoantibodies

Serbia
Applied Therapeutics, Inc.

Active, not recruiting

Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia

Classic Galactosemia

United States
Arrys Therapeutics
Merck Sharp & Dohme LLC

Completed

Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer

Microsatellite Stable Colorectal Cancer

United States
Johns Hopkins University
Juvenile Diabetes Research Foundation; iCo Therapeutics Inc.

Terminated

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) (iDEAL)

Diabetic Macular Edema

United States
Oblato, Inc.

Withdrawn

Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants

Glioblastoma | Astrocytoma | Oligodendroglioma
Better Therapeutics

Completed

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Type 2 Diabetes

United States
Arrys Therapeutics
Merck Sharp & Dohme LLC

Terminated

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Non-small Cell Lung Cancer Adenocarcinoma

United States
Fulgent Pharma LLC.

Recruiting

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

United States
Wake Forest University

Terminated

Treatment of Distal Radius Buckle Fractures

Fracture Treatment
Institute of Cancer Research, United Kingdom
Trans Tasman Radiation Oncology Group

Active, not recruiting

Study of Tumour Focused Radiotherapy for Bladder Cancer (RAIDER)

Bladder Cancer

United Kingdom, New Zealand, Australia
Castle Creek Biosciences, LLC.

Terminated

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa Dystrophica, Recessive

United States
Ribomic USA Inc

Completed

A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration (RAMEN)

Exudative Age-related Macular Degeneration

United States
Berlin Cures GmbH

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects

Healthy Volunteers

Germany
920th Hospital of Joint Logistics Support Force...

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Acute Myeloid Leukemia

China
Emory University
National Cancer Institute (NCI); Prostate Cancer Foundation

Recruiting

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Daniel Landi

Terminated

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (ExCeL)

Glioblastoma | Gliosarcoma

United States
Temple University

Completed

Diagnostic Accuracy of Handheld vs Traditional Ultrasound

Image, Body

United States
Inmagene LLC

Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

Alopecia Areata (AA)

United States, Canada
Gustavo Reyes-Teran

Recruiting

Immediate ART in Subjects With Opportunistic Diseases

HIV/AIDS | ANTIRETROVIRAL TREATMENT

Mexico
St. Josef Hospital Bochum

Unknown

Emotion, Mood and Executive Function in Parkinson's Disease (PD) (RasQ)

Parkinson Disease

Germany
Quell Therapeutics Limited

Recruiting

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients (LIBERATE)

Liver Diseases | Liver Failure | Rejection; Transplant, Liver

Belgium, United Kingdom, Spain
Kazia Therapeutics Limited

Completed

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Australia
Inmagene LLC

Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | AD

Canada, United States

Search clinical trials for: WU-CART-007

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations